Abstract
Introduction
Apolipoprotein E (APOE) is part of several types of lipoproteins including VLDL, HDL and chylomicrons [1] . Three major isoforms exist: APOE2, APOE3 and APOE4, which have allele frequencies of 6%, 15% and 78% respectively [2] . Large meta-analyses have shown that carriers of APOE4 have a modestly increased risk of coronary heart disease [3, 4] and stroke [5] compared with individuals with the APOE3/APOE3 genotype, though the magnitude of this finding differs between studies and it is not always significant [4] . Furthermore APOE4 is associated with increased levels of LDL cholesterol [4] [5] [6] and triglycerides [7] in the plasma.
For prevention of CVD, the European Society of Cardiology recommends two fatty fishcontaining meals a week [8] . A meta-analysis of randomized controlled trials showed that supplementary n-3 polyunsaturated fatty acids (PUFAs) decreases the risk of CVD [9] .
However, this positive impact on CVD is not reported consistently; several studies find no association between n-3 PUFA supplementation and CVD risk [10] . Furthermore, interindividual differences in the response to n-3 PUFAs have been observed. This inter-individual variability may, in part, be caused by genetic factors [11] .
Several studies have shown that APOE genotype influences the plasma lipid response to fishoil supplementation. Minihane et al. 2000 [12] found a significant increase in total cholesterol and a trend toward a reduction in HDL-Cholesterol in APOE4 carriers relative to APOE3/APOE3 subjects after fish-oil supplementation. In line with this, Olano-martin et al.
2010 [13] found increased total cholesterol concentrations in APOE4 carriers in response to 4 weeks docosahexaenoic acid (DHA) supplementation. Caslake et al 2008 [14] found the greatest decrease in plasma triglyceride concentration in APOE4 men after fish-oil supplementation.
We previously showed that 6 months fish-oil supplementation decreased gene expression of genes involved in inflammatory and atherogenic pathways in peripheral blood mononuclear cells (PBMCs) [15] . PBMCs are a subpopulation of circulating immune cells mainly consisting of monocytes and lymphocytes. These circulating immune cells are important players in the pathogenesis of CVD, especially atherosclerosis, and, therefore, are a suitable target for studying inflammatory and CVD mechanisms [16] . APOE genotype has been shown to affect immune cell response [17] [18] [19] . For example, mice monocytes/macrophages showed an increased inflammatory response when transfected to produce human APOE4 compared to APOE3 [17] . Moreover, signaling via the APOE receptors promotes conversion of macrophages from the pro-inflammatory M1 to the anti-inflammatory M2 phenotype [18] , which may be decreased in APOE4 carriers because of the lower APOE concentrations that are observed with APOE4 [19] . From these results, it is thought that the altered inflammatory response of APOE4-expressing monocytes/macrophages may contribute to the higher CVD risk observed in APOE4 carriers.
By measuring PBMC whole genome gene expression with microarrays and combining this with APOE genotyping, we are able to unbiasedly study genotype-specific phenotype effects.
In this study, we aimed to gain more insight in the pathways affected by APOE4 and the effect of fish-oil supplementation on these pathways by studying gene-diet interactions between APOE4 and fish-oil supplementation on whole genome gene expression. To do this, we conducted a secondary retrospective analysis according to APOE4 carrier status of the above-mentioned study [15, 20] . Firstly, we studied the effect of APOE4 on whole genome PBMC gene expression at baseline and, secondly, we studied how APOE4 influences the effects of 6 months of fish-oil supplementation on gene expression.
Material and methods

Study design
This study is a secondary retrospective analysis of a randomized, double-blind, placebocontrolled trial conducted by van de Rest et al. (2008) [20] that was originally designed to examine the effects of 6 months fish-oil supplementation on cognitive performance in 302 participants aged ≥ 65 years. In this secondary analysis, we examine differences in whole genome gene expression between APOE4 carriers and APOE4 non-carriers before and following the fish-oil intervention. Microarray data was available in 23 subjects from the high dose fish-oil group [15] , with RNA available in 92 participants. To validate findings of the microarray analyses, we performed targeted QPCR measurements in these 92 participants Design and methods of the original study were described in detail previously [20] . Briefly, participants were randomly allocated to receive a daily dose of fish-oil containing either 1800 mg or 400 mg eicosapentaenoic acid (EPA) and DHA, or a placebo oil (high-oleic sunflower oil (HOSF)) for 26 weeks. The high daily dose of fish oil provided 1093 ± 17 mg EPA and 847 ± 23 mg DHA, and the low daily dose provided 226 ± 3 mg EPA and 176 ± 4 mg DHA.
The oils were administered in 6 soft gelatin capsules daily, each of which contained 900 mg oil and 2.7 mg tocopherol as antioxidant (Banner Pharmacaps Europe BV, Tilburg, Netherlands).
Participants were recruited according to the following exclusion criteria: current or recent (<4 weeks) use of fish-oil supplements or intake of fish >4 times/week or >800 mg fish-oil/d from fish as estimated by using a fish-consumption questionnaire, serious liver disease, consumption of >4 glasses of alcohol-containing beverages per day, unable to participate as judged by the responsible medical physician, allergy to fish or fish-oil, swallowing problems, or participation in another clinical trial <2 mo before the start of the trial or at the same time.
Cognitive exclusion criteria were also used and were described previously [20] . Additionally, compliance with capsule use during a 2-week placebo run-in period had to be ≥80% on the basis of self-report. All participants gave written informed consent to participate in the study and the study protocol was approved by the Medical Ethical Committee of Wageningen University, Wageningen, the Netherlands. The study was registered at clinicaltrials.gov as NCT00124852.
Blood sampling and PBMC isolation
Fasting venous blood samples were collected at baseline and after 26 weeks of intervention.
Plasma free fatty acids and triglycerides were measured by gas-liquid chromatography, and C-reactive protein (CRP) concentrations were determined from measurements of highsensitivity CRP (hsCRP). For PBMC isolation, 4 mL blood was collected into Becton Dickinson Vacutainer Cell Preparation Tubes with sodium citrate. PBMCs were isolated immediately after blood collection according to the manufacturer's instructions. For APOE genotyping, a second blood sample was collected into a 4.5-mL EDTA Vacutainer and stored at -80°C.
APOE genotyping
APOE genotyping was done by the PCR-based restriction fragment length polymorphism method and restriction enzyme digestion with HhaI [21] . We retrospectively determined APOE genotype in 301 of the participants of the original study.
RNA extraction and microarray
RNA extraction and microarray methods were previously described by Bouwens et al. [15] and data can be found in Gene Expression Omnibus under accession number GSE12375. We reanalyzed the data using the current gene definitions (NuGOHs1a520180_Hs_ENTREZG MBNI custom CDF version 19.0.0) and grouped the samples based on the APOE genotyping results (Supporting Information table S1).
Microarray analysis was performed on baseline samples and on samples after 26 weeks of intervention, using human whole-genome NuGO GeneChip arrays designed by the European Nutrigenomics Organization and manufactured by Affymetrix (Affymetrix Inc, Santa Clara, CA). Microarrays were analyzed using MADMAX (Management and Analysis Database for Multiplatform Microarray Experiments) [22] . Expression values were normalized using the RMA (robust multichip average method) [23] . Genes with normalized expression values >20 on at least 5 arrays were defined as expressed and selected for further analysis. Expression values were log2-transformed. LIMMA [24] was used to calculate P-values and false discovery rate (FDR) q-values for each gene using t-tests with Bayesian correction. At baseline, genes were defined as differentially expressed between APOE4 carriers and noncarriers if they had P-values < 0.05. The differences in response to fish-oil supplementation were calculated using the individual log ratios. Differences in genes expression changes between APOE4 carriers and non-carriers were defined as significantly different if they had Pvalues < 0.05.
Pathway analysis and upstream transcription regulators analyses were performed using QIAGEN's Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, www.qiagen.com/ingenuity). We also performed pathway analysis using gene set enrichment analysis (GSEA; http://www.broad.mit.edu/gsea) [25] . Briefly, genes were ranked based on the t-statistic and analyzed for over-or underrepresentation in predefined gene sets. Gene sets were derived from Biocarta, KEGG, Reactome and Wikipathways pathway databases.
Genesets with a false discovery rate < 0.1 were considered significantly enriched (Supporting Information tables S2-S5).
QPCR
For qPCR, RNA was available of PBMCs of 92 participants of which 31 were carriers and 61
were non-carriers of APOE4. RNA was reverse transcribed using a cDNA synthesis kit (RevertAid First Strand cDNA Synthesis kit, Thermo Scientific, Leusden, the Netherlands) and analyzed by qPCR (SensiMix SYBR No-ROX, Bioline, London, UK) on a CFX384 RealTime System (C1000 Thermal Cycler, Biorad, Veenendaal, The Netherlands). qPCR data were normalized using the RPLP0 housekeeping gene. Genes for qPCR were selected from the differentially expressed pathways between APOE4 carriers and non-carriers. Genes needed to be differently expressed between APOE4 carriers and non-carriers and have an expression value above 200. Primers sequences are shown in Table 1 .
Statistics
Statistical analysis of subject characteristics and qPCR findings was performed using IBM SPSS Statistics, Version 22.0.0.1. A two-sided P < 0.05 was considered significant. Subject characteristics were reported as mean ± sd. Baseline characteristics of APOE4 carrier and non-carrier groups were compared using independent t-tests. QPCR results were analyzed using independent t-tests.
Power calculations were performed retrospectively for the HMGCS1 gene. Power was calculated to be 83%, using the mean expression values and standard deviations as observed (218.7 and 184.8 for APOE4 carriers; and 28.2 and 23.5 for APOE4 non-carriers).
Results
Participant characteristics
The original study consisted of 302 participants. Here, we focused on a subgroup of participants who received 1800 mg fish-oil and on whom PBMC whole genome gene expression microarray analysis was performed (N=23). APOE genotyping showed that 8 of the 23 participants were carriers of APOE4. Baseline characteristics of carriers and noncarriers are presented in Table 2 . We found no differences in any parameters between the groups. Participants received daily fish-oil supplementation containing 1800 mg of EPA and docosahexaenoic acid (DHA) for 6 months. We found no difference in the changes in any parameters between APOE4 carriers and non-carriers ( Table 2) .
Baseline
To determine the effects of APOE4 on gene expression, baseline expression profiles were compared between APOE4 carriers and non-carriers. Of the 13027 genes found to be expressed, 1320 genes were differentially expressed between carriers and non-carriers of the APOE4 SNP at P < 0.05 (Figure 1) . No genes showed an FDR q < 0.05.
To gain further insight into the biological processes affected by APOE4, we performed pathway analysis using Ingenuity Pathway Analysis on the set of differentially expressed genes at baseline. 
Information table S2).
Further inspection of the function of the genes related to cholesterol biosynthesis, showed that many of these genes are encoding enzymes involved in de novo synthesis of cholesterol.
These genes were found to be more highly expressed in APOE4 carriers than in non-carriers.
Genes involved in cholesterol uptake (LDLR and CD36) and efflux (ABCA1, ABCG1 and SCARB1) showed no difference in expression in APOE4 carriers compared to non-carriers.
We observed a higher expression of genes involved in IFN signaling in carriers compared to non-carriers of APOE4. These genes included IFN (alpha, beta and omega) receptor 1 (IFNAR1) as well as the intracellular signaling molecules Signal Transducers and Activator of Transcription (STAT)1 and STAT2. Besides IFN signaling genes, we also found a higher expression of many IFN target genes in carriers of the APOE4 SNP compared to non-carriers (Table 3 and Figure 3 ).
To examine potential regulators of the observed gene expression differences between carriers and non-carriers, we performed Ingenuity upstream regulator analysis. IFNL1, IFNA2 and IFNG were identified as potential transcriptional regulators of the observed gene expression differences. These regulators and their targets are shown in Figure 3 . Additionally, several other molecules that are involved in IFN signaling were identified as potential upstream regulators ( Table 4) .
Fish-oil intervention effect
To examine the effect of APOE4 on the gene expression response to fish-oil supplementation, we determined the genes that were differentially regulated in response to fish-oil supplementation in carriers compared to non-carriers of APOE4. We found that 866 genes showed a different change in expression caused by fish-oil supplementation between carriers and non-carriers at P < 0.05 (Figure 1) . No genes showed an FDR q < 0.05. In carriers of the APOE4 allele, genes in these IFN signaling pathways were found to be mostly downregulated, whereas non-carriers mostly showed an upregulation in response to n-3 PUFA supplementation when comparing gene expression after supplementation to expression at baseline.
To examine potential regulators of the differentially expressed genes, we performed Ingenuity upstream regulator analysis. This revealed many IFN-related genes as potential upstream transcriptional regulators, including IFNL1, IFNA2 and IFNG ( Table 5 ). The genes regulated by these cytokines were found to be largely downregulated in APOE4 carriers and largely upregulated in non-carriers, as shown in Figure 5 .
Comparison of gene expression profiles after 6 months fish-oil supplementation between carriers and non-carriers of APOE4 showed that both cholesterol biosynthesis as well as IFN signaling pathways were no longer enriched in the comparison between carriers and noncarriers of APOE4 (data not shown).
QPCR validation of the microarray findings
QPCR was used to determine the expression of five genes selected from the cholesterol biosynthesis and IFN signaling pathways in all available RNA samples. We determined gene expression of HMGCR, HMGCS1, IFITM1, STAT1 and TAP1 in a total of 92 participants, of which 31 were APOE4 carriers and 61 were APOE4 non-carriers. We found that expression of HMGCS1 and STAT1 was significantly higher in APOE4 carriers compared to non-carriers at baseline (Figure 6 ). Mean expression of HMGCR, IFITM1 and TAP1 was higher in APOE4 carriers compared to non-carriers, though these differences were not significant. Literature on the role of fish-oil or n-3 PUFAs on IFN pathways and IFN-regulated genes is scarce. It is possible that previous studies that did not take APOE genotype into account found no effects, as we show in the current study that IFN signaling-related gene expression is either upregulated or downregulated dependent on APOE genotype. We identified one mouse study, in which a high intake of n-3 PUFAs was shown to lead to diminished STAT1 phosphorylation after ex-vivo stimulation of immune cells with IFN-gamma [29] . A similar mechanism could be present in our APOE4 carriers, though, to our knowledge, no studies exist that have examined the role of APOE genotype in this context. One relatively small study in 35 Alzheimer's disease patients examined the interaction between APOE genotype and 6 months of fish-oil supplementation on several inflammatory cytokines in the plasma, but found no effects of APOE genotype [30] .
In contrast to APOE4 carriers, non-carriers showed an upregulation of IFN pathways.
Previously, we examined the effects of fish-oil supplementation in this population and found anti-inflammatory and anti-atherogenic gene expression changes when not taking APOE genotype into account [15] . These changes were not found in genes related to IFN signaling pathways. This indicates that fish-oil supplementation may have pro-inflammatory as well as anti-inflammatory effects in APOE4 non-carriers. Further research is required to fully understand the APOE genotype-specific effects of fish-oil supplementation on inflammatory signaling.
APOE4 is associated with an increased risk of CVD [4] . Partly, this is thought to be mediated by increased LDL-cholesterol and triglyceride plasma concentrations in APOE4 carriers [31] .
In the full study group of 301 participants, we also observed significantly higher LDLcholesterol levels in the plasma of APOE4 carriers compared to non-carriers. Our microarray data point towards an increase in cholesterol synthesis as reflected by a higher expression of several genes encoding enzymes involved in the synthesis of cholesterol, including HMGCoA reductase (HMGCR), the enzyme catalyzing the rate-limiting step in the synthesis of cholesterol [32] . Expression of this gene and other genes involved in cholesterol biosynthesis is known to be controlled by the SREBP-2 transcription factor through a negative feedback system [33] . Therefore, the higher expression of cholesterol biosynthesis genes in APOE4 carriers might suggests a lower intracellular cholesterol concentration and, consequently, a reduced activity of SREBP-2. However, the SREBP-2 gene itself was not differentially expressed between APOE4 carriers and non-carriers and, based on the increased LDL-cholesterol concentrations in APOE4 carriers that we observed in the full study group of 301 participants and is consistently reported in literature, one might expect increased intracellular cholesterol levels. Whether cholesterol levels are actually increased in the cell requires further investigation.
The role of increased cholesterol synthesis in monocytes remains unclear. It may promote cholesterol accumulation in these cells, which is an important first step in foam cell formation and may, therefore, potentially be related to the increased CVD risk in APOE4 carriers.
Additionally, in a study by Gerdes et al. (2000) [34] , treatment with simvastatin, an inhibitor of the HMGCR protein, abolishes the APOE4-related 2-fold increase in mortality after a previous myocardial infarction. This study indicates that persons carrying a copy of the APOE4 allele are especially sensitive to cholesterol synthesis altering interventions. HMGCR gene expression in PBMCs has been shown to closely parallel liver gene expression [35] . If the higher expression of this gene and other SREBP-2-regulated cholesterol biosynthesis genes is present in liver as well, it may possibly explain why APOE4 carriers are especially sensitive to cholesterol synthesis altering interventions with respect to CVD risk.
In this study, we describe changes in two pathways that may potentially contribute to the increased CVD risk that is observed in carriers of APOE4: (1) increased expression of IFN signaling and IFN target genes, and (2) Although the expression of genes in the cholesterol biosynthesis pathway was significantly higher in APOE4 carriers compared to non-carriers, we did not observe a significant response to fish-oil supplementation in either group. When comparing carriers and non-carriers after supplementation the cholesterol biosynthesis pathway is no longer significantly differently expressed, suggesting that fish-oil might have affected gene expression of these genes to some extent. Possibly, these changes may have gone undetected due to the relatively low number of participants, especially in the APOE4 group.
A limitation of this study is that, due to the fact that it was not originally designed to answer the current research question, the groups are relatively small and not of the same size. We performed power calculations, which showed that we had sufficient power for the microarray analyses. Distinct differences in gene expression between carriers and non-carriers of the APOE4 allele, both at baseline as well as in the response to a 6-month fish-oil intervention were observed. Furthermore, several of the differences at baseline were confirmed in a larger group using qPCR. For our microarray analyses, we used a relatively high P-value cut-off of 0.05. Using FDR q-values for selecting the differentially expressed genes did not yield results in several comparisons. For this reason, we focused our analyses mainly on the pathway level.
In this study, we opted not to include to placebo group in the analysis [15] . Firstly, because our study is focused on the differences between APOE4 carriers and non-carriers in the response to fish-oil. Secondly, adding this group, would further complicate this already quite complicated analysis and, as a consequence, reduce the readability of the paper.
The opposite effect of fish-oil supplementation in APOE4 carriers and non-carriers that we found, can partially explain the heterogeneity that is seen in the responses to fish-oil supplementation on gene expression profiles and illustrates the importance of research on diet-gene interactions and research into personalized nutrition in general.
Our findings related to IFN signaling and cholesterol biosynthesis might explain part of the association between APOE4 and the increased risk of CVD that is observed in carriers of this allele. Additionally, with respect to our IFN signaling gene expression results we hypothesize that fish-oil supplementation may particularly benefit APOE4 carriers. shown. P-values were considered significant when P < 0.05. Fisher's exact test.
